FeesSafety
Pluang+

Evernorth may issue 5.2M shares at 3% discount to fund XRP treasury expansion, risking shareholder dilution.

Protocol Fundamentals
10 Nov 2026, 14:33 WIB
Coinpaper
View Source
Neutral
Evernorth may issue 5.2M shares at 3% discount to fund XRP treasury expansion, risking shareholder dilution.

Evernorth Holdings plans to issue up to 5.2 million new shares at a 3% discount through a financing deal with Cantor, potentially raising over $50 million to buy more XRP. This move could dilute existing shareholders by about 16.7% of the expanded Class A shares but aims to increase XRP holdings per share. The company uses multiple capital strategies to support its XRP treasury amid challenging market conditions, with partnerships including Ripple and Coinbase. The success depends on XRP price trends and effective capital use to offset dilution.

Evernorth's plan to sell 5.2 million shares at a slight discount to fund XRP expansion provides context for cryptocurrency market activity. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Nov 10, 2026 19:44 WIB: out of 50 priced assets, 30 rose and 19 fell. Notable movers include BCH at Rp4.263.079 with a 3.07% decline and a Pluang order activity of 10% Sell / 90% Buy, AVAX at Rp150.596 up 3.02% with 59% Sell / 41% Buy, and XNO at Rp5.785 up 2.92% with 0% Sell / 100% Buy. Typical hold times range from 69 to 88 days.

More News

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...

Market News
Neutral
57 minutes ago
Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...

Market News
Bullish
57 minutes ago
PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...

Company Fundamentals
Bullish
57 minutes ago
Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...

Company Fundamentals
Bullish
57 minutes ago
Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App